What is the appropriate lansoprazole dosing for a 10‑month‑old infant (approximately 8–10 kg)?

Lansoprazole Dosing for a 10-Month-Old Infant

Lansoprazole is not recommended for infants under 12 months of age because controlled trials have demonstrated no efficacy for symptomatic GERD in this population, and safety and effectiveness have not been established. 1

FDA-Approved Age Restrictions

• The FDA label explicitly states that lansoprazole was not effective in a multicenter, double-blind, placebo-controlled study of 162 infants aged 1 month to less than 12 months with symptomatic GERD 1
• Both the lansoprazole group and placebo group showed identical response rates (54% in both groups), demonstrating no therapeutic benefit 1
• Safety and effectiveness have not been established in patients less than one year of age 1
• FDA approval for lansoprazole begins at ≥1 year of age 1

Age-Specific Pharmacokinetic Concerns

If lansoprazole were to be considered off-label (which is not recommended), critical age-dependent dosing differences exist:

• Infants ≤10 weeks of age have 2-fold higher peak concentrations, 3-fold longer half-lives, and 5-fold higher drug exposure compared to older infants 2
• These younger infants require substantially lower doses (0.2–0.3 mg/kg/day for ≤10 weeks vs. 1.0–1.5 mg/kg/day for >10 weeks) to achieve comparable plasma levels 1, 2
• A 10-month-old infant falls into the older category but still lacks proven efficacy 2

Safety Concerns in This Age Group

• In the failed efficacy trial, serious adverse events—particularly lower respiratory tract infections—were significantly increased in PPI-treated infants (OR 6.56,95% CI 1.18–26.25) 3
• Long-term PPI use in children has been associated with increased infections, vitamin B12 deficiency, and bone fractures 3
• Nonclinical juvenile animal studies demonstrated heart valve thickening and bone changes at doses above the maximum recommended human equivalent 1

Guideline Recommendations

• The 2018 CHEST guidelines and multiple systematic reviews conclude that PPIs should not be routinely used for chronic cough or unspecific GERD symptoms in infants 3
• A 2023 Cochrane review found very low-certainty evidence that omeprazole and esomeprazole provide no additional symptom reduction compared to placebo in infants 4
• Current guidelines emphasize that GERD in infancy is generally self-limiting and improves with age, favoring nonpharmacologic management 3, 4

Clinical Algorithm

For a 10-month-old with suspected GERD:

1. First-line: Implement dietary and lifestyle modifications (positioning, smaller/more frequent feeds, thickened feeds if appropriate) 3
2. Reassess diagnosis: Ensure symptoms truly represent GERD requiring treatment versus normal physiologic reflux 3, 4
3. Avoid lansoprazole: Given lack of proven efficacy and potential harms in this age group 1
4. If pharmacotherapy is absolutely necessary (erosive esophagitis confirmed by endoscopy), consider waiting until ≥12 months of age when FDA-approved dosing begins: 15 mg daily for weight ≤30 kg 1

Critical Pitfall

The most common error is prescribing PPIs for typical infant regurgitation or fussiness, which are usually not GERD and do not benefit from acid suppression 3, 4. The placebo response rate in the pivotal trial was 54%, highlighting that many symptoms resolve regardless of treatment 1.